Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma 3Leukemia 3Lymphoma, B-Cell, Marginal Zone 2Waldenstrom Macroglobulinemia 1Mastocytosis, Systemic 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1

Interventions

midostaurin 3avapritinib 2ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Ranitidine 1Interviews as Topic 1Imatinib Mesylate 1Ibuprofen 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × denileukin diftitox × Other hematologic neoplasm × Clear all
NCT00493129 2012-02-08

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

M.D. Anderson Cancer Center

Phase 2 Completed
8 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡